BioNTech Drug Shows Modest PFS Improvement Versus Chemotherapy
Trastuzumab pamirtecan showed a modest progression-free survival improvement versus chemotherapy in HR+/HER2-low metastatic breast cancer.
Trastuzumab pamirtecan showed a modest progression-free survival improvement versus chemotherapy in HR+/HER2-low metastatic breast cancer.